Matches in SemOpenAlex for { <https://semopenalex.org/work/W2413099979> ?p ?o ?g. }
Showing items 1 to 62 of
62
with 100 items per page.
- W2413099979 endingPage "6" @default.
- W2413099979 startingPage "131" @default.
- W2413099979 abstract "To determine the feasibility and the economic impact of tumour EGFR, erbB-2 and cathepsin-D measurements in women with node-negative breast cancer.Consecutive tumour samples received at a regional steroid receptor laboratory from patients with node-negative breast cancer were evaluated with commercially available kits to determine EGFR, erbB-2 and cathepsin-D levels.All node-negative patients whose tumours were submitted to the steroid receptor laboratory from November 1992 to March 1994 were included (n = 142). A control group of concurrent node-negative breast cancer patients from the London Regional Cancer Centre (LRCC) database were also evaluated to determine the representativeness of our sample.To determine the proportion of patients who were positive for the 3 newer prognostic factors relative to their risk of relapse.We found 75 positive values in 69 patients (48.6%). We demonstrated that each factor identified a different high-risk subgroup. Epidermal growth factor receptor (EGFR) positivity (> 10 fmol/mg protein) was found in 16.3% of patients, with 19.9% of patients positive for erbB-2 (> 250 units/mg protein) and 17.3% positive for cathepsin D (> 70 pmol/mg protein). Between 10% and 23.2% more node-negative patients currently seen in a regional cancer centre could be offered systemic adjuvant chemotherapy based on a single positive new factor.These tumour evaluations are straightforward using material already available in a regional steroid receptor laboratory or on tumour tissue available to pathologists. The economic impact is minimal; the 1995 cost of performing all 3 evaluations is Can$425-616 (US$304-440) per patient treated depending on the number of assays per run. Prospective clinical trials incorporating tumour EGFR, erbB-2 and cathepsin D are feasible and economically viable." @default.
- W2413099979 created "2016-06-24" @default.
- W2413099979 creator A5014687335 @default.
- W2413099979 creator A5075456930 @default.
- W2413099979 creator A5080592567 @default.
- W2413099979 creator A5084704365 @default.
- W2413099979 creator A5087702098 @default.
- W2413099979 date "1999-04-01" @default.
- W2413099979 modified "2023-09-26" @default.
- W2413099979 title "Tumour epidermal growth factor receptor, erbB-2 and cathepsin D in node-negative invasive breast cancer: their impact on the selection of patients for systemic adjuvant therapy." @default.
- W2413099979 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/10474760" @default.
- W2413099979 hasPublicationYear "1999" @default.
- W2413099979 type Work @default.
- W2413099979 sameAs 2413099979 @default.
- W2413099979 citedByCount "0" @default.
- W2413099979 crossrefType "journal-article" @default.
- W2413099979 hasAuthorship W2413099979A5014687335 @default.
- W2413099979 hasAuthorship W2413099979A5075456930 @default.
- W2413099979 hasAuthorship W2413099979A5080592567 @default.
- W2413099979 hasAuthorship W2413099979A5084704365 @default.
- W2413099979 hasAuthorship W2413099979A5087702098 @default.
- W2413099979 hasConcept C121608353 @default.
- W2413099979 hasConcept C126322002 @default.
- W2413099979 hasConcept C143998085 @default.
- W2413099979 hasConcept C173633252 @default.
- W2413099979 hasConcept C181199279 @default.
- W2413099979 hasConcept C2779438470 @default.
- W2413099979 hasConcept C530470458 @default.
- W2413099979 hasConcept C55493867 @default.
- W2413099979 hasConcept C71924100 @default.
- W2413099979 hasConcept C86803240 @default.
- W2413099979 hasConceptScore W2413099979C121608353 @default.
- W2413099979 hasConceptScore W2413099979C126322002 @default.
- W2413099979 hasConceptScore W2413099979C143998085 @default.
- W2413099979 hasConceptScore W2413099979C173633252 @default.
- W2413099979 hasConceptScore W2413099979C181199279 @default.
- W2413099979 hasConceptScore W2413099979C2779438470 @default.
- W2413099979 hasConceptScore W2413099979C530470458 @default.
- W2413099979 hasConceptScore W2413099979C55493867 @default.
- W2413099979 hasConceptScore W2413099979C71924100 @default.
- W2413099979 hasConceptScore W2413099979C86803240 @default.
- W2413099979 hasIssue "2" @default.
- W2413099979 hasLocation W24130999791 @default.
- W2413099979 hasOpenAccess W2413099979 @default.
- W2413099979 hasPrimaryLocation W24130999791 @default.
- W2413099979 hasRelatedWork W2050645819 @default.
- W2413099979 hasRelatedWork W2082618958 @default.
- W2413099979 hasRelatedWork W2085880972 @default.
- W2413099979 hasRelatedWork W2086925712 @default.
- W2413099979 hasRelatedWork W2224319365 @default.
- W2413099979 hasRelatedWork W2413099979 @default.
- W2413099979 hasRelatedWork W2477020619 @default.
- W2413099979 hasRelatedWork W2747344780 @default.
- W2413099979 hasRelatedWork W2803053501 @default.
- W2413099979 hasRelatedWork W4212768473 @default.
- W2413099979 hasVolume "3" @default.
- W2413099979 isParatext "false" @default.
- W2413099979 isRetracted "false" @default.
- W2413099979 magId "2413099979" @default.
- W2413099979 workType "article" @default.